WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205643
Description: TH9402 is a dibrominated rhodamine derivative and potent photosensitizer and useful in photodynamic therapy. TH9402 eradicates multiple myeloma (MM) and BC cell lines, while sparing more than 50% of normal pluripotential blood stem cells from healthy volunteers. TH9402 offers an excellent potential as an ex vivo photodynamic purging agent for autologous transplantation in MM and BC treatment.
MedKoo Cat#: 205643
Chemical Formula: C21H15Br2ClN2O3
Exact Mass: 535.9138
Molecular Weight: 538.62
Elemental Analysis: C, 46.83; H, 2.81; Br, 29.67; Cl, 6.58; N, 5.20; O, 8.91
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: TH9402; TH-9402; TH 9402; Xanthylium.
IUPAC/Chemical Name: 3,6-diamino-4,5-dibromo-9-(2-(methoxycarbonyl)phenyl)xanthylium chloride
SMILES Code: O=C(C1=CC=CC=C1C2=C3C=CC(N)=C(Br)C3=[O+]C4=C2C=CC(N)=C4Br)OC.[Cl-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 538.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Tregs served sunny-side up By Betts, Brian C.; Young, James W. From Blood (2010), 116(23), 4736-4737.
2. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique By Mielke, Stephan; Nunes, Raquel; Rezvani, Katayoun; Fellowes, Vicki S.; Venne, Annie; Solomon, Scott R.; Fan, Yong; Gostick, Emma; Price, David A.; Scotto, Christian; et al From Blood (2008), 111(8), 4392-4402.
3. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation By Perruccio, Katia; Topini, Fabiana; Tosti, Antonella; Carotti, Alessandra; Aloisi, Teresa; Aversa, Franco; Martelli, Massimo F.; Velardi, Andrea From Blood Cells, Molecules, & Diseases (2008), 40(1), 76-83.
4. Quaternized phthalocyanines and method for photodisinfection of water By Vorozhtsov, G. N.; Kaliya, O. L.; Kuznetsova, N. A.; Luzhkov, Yu. M.; Luk'yanets, E. A.; Makarov, D. A.; Negrimovskii, V. M.; Slivka, L. K.; Yuzhakova, O. A. From Russ. (2006), RU 2281953 C1 20060820.
5. Specific elimination of alloreactive T-cells using a novel photosensitizer, a TH9402, for the prophylaxis of GvHD: A review By Villancourt, M.; Roy, D. C.; Chao, N.; Boumedine, R. Sidi; Guimond, M.; Chen, B.; Su, H. From Immunology 2004, [12th International Congress of Immunology and 4th Annual Conference of FOCIS], Montreal, QC, Canada, July 18-23, 2004 (2004), E718C5831/1-E718C5831/9.
6. Photodynamic therapy (PDT)-treated cells in preparation of vaccines for prevention, protection, prophylaxis or treatment of immunological disorders, infections, and cancer By Roy, Denis Claude; Vaillancourt, Marc; Villeneuve, Luc From PCT Int. Appl. (2005), WO 2005053743 A1 20050616.
7. Bromorhodamines as efficient photosensitizers in the formation of singlet molecular oxygen in aqueous and ethanolic solutions By Butorina, D. N.; Krasnovskii, A. A.; Savvina, L. P.; Kuznetsova, N. A. From Russian Journal of Physical Chemistry (2005), 79(5), 791-794.
8. Elimination of alloreactive T cells using photodynamic therapy By Boumedine, R. Sidi; Roy, D. C. From Cytotherapy (2005), 7(2), 134-143.
9. Depletion of Host Reactive T Cells by Photodynamic Cell Purging and Prevention of Graft Versus Host Disease By Goggins, Timothy F.; Chao, Nelson From Leukemia & Lymphoma (2003), 44(11), 1871-1879.
10. Photo-disinfecting of water By Alexeeva, Vera Ivanovna; Vorozhtsov, Georgy Nikolaevich; Kaliya, Oleg Leonidovich; Kuznetsova, Nina Alexandrovna; Luzhkov, Yury Mikhailovich; Avgustinchik, Galina Fedorovna; Gorina, Elena Nikolaevna; Koverga, Alexandr Vitalievich; Lukyanets, Evgeny Antonovich; Negrimovsky, Vladimir Mikhailovich; et al From PCT Int. Appl. (2003), WO 2003068690 A1 20030821.
11. P-glycoprotein targeting: a unique strategy to selectively eliminate immunoreactive T cells By Guimond, Martin; Balassy, Antonia; Barrette, Melanie; Brochu, Sylvie; Perreault, Claude; Roy, Denis Claude From Blood (2002), 100(2), 375-382.
12. Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process By Chen, Benny J.; Cui, Xiuyu; Liu, Congxiao; Chao, Nelson J. From Blood (2002), 99(9), 3083-3088.
13. Eradication of multiple myeloma and breast cancer cells by TH9402-mediated photodynamic therapy: implication for clinical ex vivo purging of autologous stem cell transplants By Brasseur, N.; Menard, I.; Forget, A.; El Jastimi, R.; Hamel, R.; Molfino, N. A.; Van Lier, J. E. From Photochemistry and Photobiology (2000), 72(6), 780-787.
14. Ex vivo photodynamic purging in chronic myelogenous leukemia and other neoplasias with rhodamine derivatives By Villeneuve, Luc From Biotechnology and Applied Biochemistry (1999), 30(1), 1-17.
15. Spectroscopic and photophysical investigations on the nature of localization of rhodamine-123 and its dibromo derivative in different cell lines By Villeneuve, Luc; Pal, Prabir; Durocher, Gilles; Migneault, David; Girard, Denis; Giasson, Richard; Balassy, Antonia; Blanchard, Louise; Gaboury, Louis From Journal of Fluorescence (1996), 6(4), 209-219.
16. Spectroscopic and photophysical properties of some new rhodamine derivatives in cationic, anionic and neutral micelles By Pal, P.; Zeng, H.; Durocher, G.; Girard, D.; Giasson, R.; Blanchard, L.; Gaboury, L.; Villeneuve, L. From Journal of Photochemistry and Photobiology, A: Chemistry (1996), 98(1-2), 65-72.
17. Phototoxicity of some bromine-substituted rhodamine dyes: synthesis, photophysical properties and application as photosensitizers By Pal, PRabir; Zeng, Hualing; Durocher, Gilles; Girard, Denis; Li, Tiechao; Gupta, Ajay K.; Giasson, Richard; Blanchard, Louise; Gaboury, Louis; et al. From Photochemistry and Photobiology (1996), 63(2), 161-8.